Dr. John Cush RheumNow
1 year 9 months ago
post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8 https://t.co/tB9sd9VS1K
Dr. John Cush RheumNow
1 year 9 months ago
Metanalysis of 5063 SLE patients, found fibromyalgia (FM) 15.8% (high heterogeneity I2- 98%). SLE pts had a 3.7 fold higher risk of FM. FM in SLE was a confounder in assessing disease activity and treatment response. FM is a frequent comorbidity in SLE https://t.co/0fSIl480PG https://t.co/6ZtAovPVnD
Dr. John Cush RheumNow
1 year 9 months ago
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/Cbzi00xHdb https://t.co/JLSIyOdxKb
Dr. John Cush RheumNow
1 year 9 months ago
JAK inhibitors are effective at repigmentation in vitiligo. 5 RCTs, 1,550 pts showed >50% improvement (TVASI50; RR 2.67) or >75% (FVASI75; RR 3.97_ JAKi increased skin AE, but not significantly different from placebo pts. https://t.co/zIreYlUyLt https://t.co/pCWKL2vSVs
Dr. John Cush RheumNow
1 year 9 months ago
Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Metanalysis of 10 studies shows reactivation in 21% of HBsAg+ patients without prophylaxis vs 4.4% in HBsAg−/HBcAb+ patients. https://t.co/eHzIeA8uJK https://t.co/CmZw8C8ibn
Dr. John Cush RheumNow
1 year 9 months ago
Outcomes Comparison study of late-onset RA (LORA) vs younger-onset RA (YORA) showed similar Dz activity assessments over 5 years but Late onset RA had worse functional outcomes and more adverse events (adj HR 4.7 for death & 2.6 for malignancy). https://t.co/b58zJG1OuA https://t.co/WZa12O06Rf
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Dr. John Cush RheumNow
1 year 9 months ago
Online survey of 1,531 in 2019 showed that rural women have greater psychological and physical burdens than their suburban/urban women - with more mood swings, muscle and joint pain, vaginal dryness and urinary problems . https://t.co/TlaEEENdzp https://t.co/TTtyWK5urZ
Dr. John Cush RheumNow
1 year 9 months ago
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/vkoA3UHZGg
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/jIzOzPIcML https://t.co/EB2clBvq0g
Dr. John Cush RheumNow
1 year 9 months ago
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia. The increasing prevalence of sedentary lifestyles parallels the increases in both obesity and gout.
Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.
Dr. John Cush RheumNow
1 year 9 months ago
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI
Dr. John Cush RheumNow
1 year 9 months ago
Best of 2024: Eating for Rheumatoid Arthritis
https://t.co/gtK3F6FdEB https://t.co/ILA6lSohh7
Dr. John Cush RheumNow
1 year 9 months ago
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/rFOW4OpZS7 https://t.co/A0EN8b9KYB
